- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.01. | Tevogen Bio and Microsoft expand AI collaboration to PredicTcell tech | ||
| 27.01. | Leading Strategic Intelligence Solutions for the Pharmaceteutical Industry | ||
| 27.01. | BIA report: UK biotech investment surged to £3.5bn in 2024 | ||
| 27.01. | Eisai and Biogen's LEQEMBI sBLA set for Alzheimer's maintenance dosing | ||
| 27.01. | Trying Times for Biopharmaceuticals: How Researchers Can Flourish Amid Industry Challenges | ||
| 27.01. | Amgen opens new drug substance facility in North Carolina, US | ||
| 24.01. | FDA approves drug application for Lupin's heart failure therapy | ||
| 24.01. | Podcast: Adaptive logistics in a changing clinical landscape | ||
| 24.01. | Stealth faces another hurdle as FDA delays decision on Barth syndrome drug | ||
| 24.01. | Emcure Pharmaceuticals opens new R&D centre in Gujarat, India | ||
| 24.01. | AbbVie and Neomorph link on oncology/immunology glue degraders | ||
| 23.01. | Magazine: The biggest challenges clinical trials will face in 2025 | ||
| 23.01. | Biogen's higher dose Spinraza under review by US and EU regulators | ||
| 23.01. | FDA grants ODD status to Zai Lab's lung cancer treatment | ||
| 23.01. | Emergent seeking to reverse fortunes and become a major overdose treatment player | ||
| 23.01. | Disc raises $225.5m as it eyes approval of rare skin disorder drug | ||
| 23.01. | Cellipont and Secretome link to manufacture cGMP cellular therapy | ||
| 23.01. | FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases | ||
| 23.01. | Comprehensive EPCM(v) Services by ZETA: Ensuring Excellence in Pharmaceutical and Biotech Projects | ||
| 23.01. | Viralgen and Axovia to develop gene therapy for retinal dystrophy | ||
| 23.01. | Pharmaceutical Technology Excellence Awards 2024: Catalent | ||
| 22.01. | AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi | ||
| 22.01. | Glox to develop precision antibiotics for cystic fibrosis | ||
| 22.01. | Atara's T cell programmes hit with clinical hold after third-party site woes | ||
| 22.01. | J&J's Spravato receives FDA label expansion for depression monotherapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
